Gadgets

For diabetics have created a drug that helps both the heart and kidneys.


Kidney disease very often bothers peoplediabetes patients. Therefore, the news that scientists have completed early clinical trials of a new drug is particularly relevant. Moreover, the research results were higher than expected. The new drug has shown its effectiveness not only in the fight against renal failure, but also in the prevention of cardiovascular complications.

Worldwide, approximately 850 million people suffer fromkidney disease. The increased incidence of diabetes exacerbates this problem. And in patients with type 2 diabetes and kidney disease, the risk of serious complications is high. Studies show that the new development called “kanagliflozin” is effective in reducing the complications of diabetes in the cardiovascular system and kidneys.

The study involved 4,400 people withkidney disease. On average, they were observed for 2.6 years. At the same time, the experiment was completed earlier than planned, since during this time experts had made quite optimistic conclusions. Each of the patients received therapy that corresponded to his condition. Then volunteers were randomly divided into 2 groups. One was given a placebo, the other - kanagliflozin at a dosage of 100 milligrams per day. For those who took canagliflozin, the risk of developing renal failure fell by 30%, while mortality against the background of this complication fell by 34%. Moreover, this group of patients also noted a reduction in the risk of mortality due to cardiovascular complications, including the risk of stroke and heart attack.


The authors of the study separately emphasized thata drug was found that simultaneously reduces the risks of cardiovascular pathologies and renal failure in patients with diabetes, and also improves the survival prognosis. This is very important because type 2 diabetes has recently become widespread. Scientists believe that the "epidemic" is associated with unhealthy diets and the use of a number of food additives.

Source: nejm.org